Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.

Recent trials have questioned the clinical benefit of beta-blockers in post-myocardial infarction (MI) patients with preserved left ventricular ejection fraction (LVEF). However, differences in pathophysiology and risk profile between MI with and without ST-segment elevation (STEMI and NSTEMI) may i...

Descripción completa

Detalles Bibliográficos
Autores: Raposeiras-Roubín, Sergio, Anguita, Manuel, Latini, Roberto, Domínguez-Rodríguez, Alberto, Barrabés, José A, Sánchez, Pedro L, Ottani, Filippo, Pocock, Stuart, Owen, Ruth, Cristobo, Pablo, Gómez-Talavera, Sandra, Staszewsky, Lidia, Escalera, Noemí, Fernández-Vázquez, Felipe, Bianco, Matteo, Prada-Delgado, Óscar, Pérez-García, Carlos Nicolás, Pelizzoni, Valentina, Navarro, Felipe, Pérez-Rivera, José-Ángel, Martín-Gorria, Gonzalo, Vetrano, Alfredo, Fuster, Valentín, Rosselló, Xavier, Ibáñez, Borja
Tipo de recurso: artículo
Fecha de publicación:2026
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:dnet:repisalud__::9e3b9a705da2414a497e34c3243ade62
Acceso en línea:https://hdl.handle.net/20.500.12105/27446
Access Level:acceso abierto
Palabra clave:Acute coronary syndrome
Beta-blockers
Bloqueadores beta
Ensayo clínico aleatorizado
IAMCEST
IAMSEST
NSTEMI
Randomized controlled trial
STEMI
Síndrome coronario agudo
Descripción
Sumario:Recent trials have questioned the clinical benefit of beta-blockers in post-myocardial infarction (MI) patients with preserved left ventricular ejection fraction (LVEF). However, differences in pathophysiology and risk profile between MI with and without ST-segment elevation (STEMI and NSTEMI) may influence the effect of beta-blockers. In this prespecified subgroup analysis of the REBOOT trial, which randomized invasively managed MI patients with LVEF > 40% to beta-blockers or control, we evaluated differences in long-term effects of the intervention between STEMI (n = 4296) and NSTEMI (n = 4142). The primary endpoint was a composite of all-cause death, reinfarction, or heart failure hospitalization over a median follow-up of 3.7 years.

Similares en LA Referencia